As the underlying basis for common inflammatory disorders, particularly psoriasis and atopic dermatitis, has been unraveled, monoclonal antibodies (biologics) that target the pathogenic immune skewing in these disorders have become available. Tumor necrosis factor (TNF) inhibitors and, more recently, inhibitors of the T helper cell (TH) 17/interleukin 23 (IL-23) pathway have revolutionized the care of individuals with moderate-to-severe psoriasis. More recently, dupilumab, which inhibits the IL-4/IL-13 receptor, became the first TH2 pathway inhibitor for individuals with moderate-to-severe atopic dermatitis.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Paller AS. Pathogenesis-Based Therapy With Repurposed Biologics for Monogenic Inflammatory Skin Disorders. JAMA Dermatol. 2020;156(8):839–841. doi:10.1001/jamadermatol.2020.1018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: